Jan. 22, 2026 -- PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced the closing of a Series B extension, bringing the company's total Series B financing to $77 million, and the dosing of the first patient in a Phase 1 clinical trial evaluating PT0511, the company's pan-KRAS degrader. The Series B extension builds on PAQ's previously announced Series B financing, with participation from existing as

Mendra, Inc. (“Mendra”), a biopharmaceutical company built to advance promising therapies for rare disease medicines, utilizing artificial intelligence (AI), today announced its launch in conjunction with the closing of an $82 million oversubscribed Series A financing. The round was co-led by OrbiMed, 8VC, and 5AM Ventures with participation from Lux Capital and Wing VC. Mendra aims to modernize the development and commercialization of rare disease therapies to more efficiently reach patients o

Infinitopes said Wednesday it closed the second tranche of its seed financing round, raising an additional $15.4 million to bring total proceeds to $35.1 million, as the UK-based biotech prepares to launch a first-in-human study of its lead asset ITOP1 — an 'off-the-shelf' precision cancer vaccine targeting oesophageal cancer recurrence. The latest investment was co-led by Octopus Ventures and new backer Amplify Bio, with participation from new investor Macmillan Cancer Support and existing sup

Jan. 20, 2026 -- Think Bioscience ("Think Bio"), a biotechnology company focused on unlocking elusive drug targets, has raised $55M in an oversubscribed Series A. The round was led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors with participation from T.A. Springer, CE-Ventures, MBX Capital, and YK Bioventures. Returning investors include AV8 Ventures, CU Innovations, and Buff Gold Ventures. Think Bioscience develops small molecule drugs for historically challenging

Jan. 16, 2026 -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on January 15, 2026, Elicio granted an aggregate of 22,400 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were appr

Jan. 14, 2026 -- MedWatch Technologies today announced that Stead Impact Ventures has committed to lead its $15M Series A financing, supporting the company’s mission to advance metabolic wellness through the development of a non-invasive biosensor for glucose-related insight and an integrated lifestyle coaching platform (currently under development). MedWatch has achieved key technical milestones in the development of its proprietary biosensing technology and is preparing for the next phase of

Jan. 13, 2026 -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, is pleased to announce a non-brokered private placement of up to 3,500,000 units of the Company (the “Units”) at a price of $1.00 per Unit, for aggregate gross proceeds of up to $3,500,000 CDN (the “Offering”). Each Unit will consist of

Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules Jan. 12, 2026 -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5 million in gross proceeds thro

Dec. 30, 2025 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility. The new aggregate $980 million credit facility will mature in 2030 and consists of a $580 million initial Term Loan, $300 million Delayed Draw Term Loan, and $100 million revolving credit facility (collectively the “Credit Facility”). The initial Term Loan was used to repay approximately $581 million of principal representing the entire remaining balance of th

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time 18, 2025 -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical comp